PMID- 25735391
OWN - NLM
STAT- MEDLINE
DCOM- 20151208
LR  - 20190606
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 16
IP  - 3
DP  - 2015
TI  - Prognostic factors influencing clinical outcomes of malignant glioblastoma 
      multiforme: clinical, immunophenotypic, and fluorescence in situ hybridization 
      findings for 1p19q in 816 chinese cases.
PG  - 971-7
AB  - Malignant glioblastoma multiforme (GBM) is the most malignant brain tumor and 
      despite recent advances in diagnostics and treatment prognosis remains poor. In 
      this retrospective study, we assessed the clinical and radiological parameters, 
      as well as fluorescence in situ hybridization (FISH) of 1p19q deletion, in a 
      series of cases. A total of 816 patients with GBM who received surgery and 
      radiation between January 2010 and May 2014 were included in this study. 
      Kaplan-Meier survival analysis and Cox regression analysis were used to find the 
      factors independently influencing patient progression free survival (PFS) and 
      overall survival (OS). Age at diagnosis, preoperative Karnofsky Performance Scale 
      (KPS) score, KPS score change at 2 weeks after operation, neurological deficit 
      symptoms, tumor resection extent, maximal tumor diameter, involvement of eloquent 
      cortex or deep structure, involvement of brain lobe, Ki-67 and MMP9 expression 
      level and adjuvant chemotherapy were statistically significant factors (p<0.05) 
      for both PFS and OS in the univariate analysis. Cox proportional hazards modeling 
      revealed that age </=50 years, preoperative KPS score >/=80, KPS score change after 
      operation >/=0, involvement of single frontal lobe, deep structure involvement, low 
      Ki-67 and MMP9 expression and adjuvant chemotherapy were independent favorable 
      factors (p<0.05) for patient clinical outcomes.
FAU - Qin, Jun-Jie
AU  - Qin JJ
AD  - Department of Neuropathology, Beijing Neurosurgical Institute, Capital Medical 
      University, Beijing, China E-mail : liguilin2014@126.com, xiejianw@sina.com.
FAU - Liu, Zhao-Xia
AU  - Liu ZX
FAU - Wang, Jun-Mei
AU  - Wang JM
FAU - Du, Jiang
AU  - Du J
FAU - Xu, Li
AU  - Xu L
FAU - Zeng, Chun
AU  - Zeng C
FAU - Han, Wu
AU  - Han W
FAU - Li, Zhi-Dong
AU  - Li ZD
FAU - Xie, Jian
AU  - Xie J
FAU - Li, Gui-Lin
AU  - Li GL
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
SB  - IM
MH  - Brain Neoplasms/*genetics/mortality/*pathology/therapy
MH  - Chromosomes, Human, Pair 1/*genetics
MH  - Combined Modality Therapy
MH  - Female
MH  - Follow-Up Studies
MH  - Glioblastoma/*genetics/mortality/*pathology/therapy
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Karnofsky Performance Status
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Retrospective Studies
MH  - Survival Rate
EDAT- 2015/03/05 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/03/05 06:00
PHST- 2015/03/05 06:00 [entrez]
PHST- 2015/03/05 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - 10.7314/apjcp.2015.16.3.971 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2015;16(3):971-7. doi: 10.7314/apjcp.2015.16.3.971.